Visual prognosis appears generally good after PPV for retained lens material

Article

An analysis of visual outcomes in a contemporary series of cataract surgery eyes that underwent pars plana vitrectomy (PPV) for retained lens material indicates these complicated cases tend to do well.

An analysis of visual outcomes in a contemporary series of cataract surgery eyes that underwent pars plana vitrectomy (PPV) for retained lens material indicates these complicated cases tend to do well, said Lawrence Y. Ho, MD.

Dr. Ho reported the findings from a retrospective review that included analyses for predictors of good and poor visual outcomes. The series included 166 consecutive cases from a 6-year period extending from January 2001 to January 2007. Follow-up exceeded 6 months in more than 80% of eyes. The visual results showed 72% of eyes achieved vision of 20/40 or better while only 10.8% ended up with vision of 20/200 or worse.

"The outcomes in this series surpass those in prior large series that showed only 58% of patients had vision of 20/40 or better while almost 18% saw 20/200 or worse. We believe improvements in both phaco technology and vitrectomy combined with earlier detection of treatment complications, such as CME with more widespread use of OCT, may account for the difference. However, this warrants further investigation," said Dr. Ho.

Predictors of vision outcomes were examined in a multivariate analysis. Better presenting vision, insertion of a posterior chamber IOL, and absence of preoperative eye disease were associated with a good vision outcome.

Development of glaucoma and presence of preexisting eye disease were associated with a poor vision outcome while anterior vitrectomy at the time of cataract surgery and sulcus lens placement at cataract surgery had protective value.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
© 2025 MJH Life Sciences

All rights reserved.